about
Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan's National Health Insurance claims database and review of current eviKetorolac in the era of cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs: a systematic review of efficacy, side effects, and regulatory issues.Synergistic Effects of Citalopram and Morphine in the Renal Colic Pain Relief; a Randomized Clinical Trial.Effects of acute administration of ketorolac on mammalian vestibular sensory evoked potentialsEvaluation of alternative strategies to optimize ketorolac transdermal delivery.Sniffing out pain: An in vivo intranasal study of analgesic efficacy.Effect of Intravenous Ketorolac on Postoperative Pain in Mandibular Fracture Surgery; A Randomized, Double-Blind, Placebo-Controlled Trial.Retrospective analysis of perioperative ketorolac and postoperative bleeding in reduction mammoplasty.Prodrug strategies for enhancing the percutaneous absorption of drugs.Pharmacological Management of Cancer-Related Pain.Combined perianal-intrarectal (PI) lidocaine-prilocaine (LP) cream and lidocaine-ketorolac gel provide better pain relief than combined PI LP cream and periprostatic nerve block during transrectal prostate biopsy.Lipid nanocapsule-based gels for enhancement of transdermal delivery of ketorolac tromethamine.Acute renal failure after influenza vaccination: a case report.Optimization of In - vitro Permeation Pattern of Ketorolac Tromethamine Transdermal Patches.Potential of cyclodextrin complexation and liposomes in topical delivery of ketorolac: in vitro and in vivo evaluation.Urinary protein profiles in ketorolac-associated acute kidney injury in patients undergoing orthopedic day surgery.Transdermal delivery of ketorolac tromethamine: effects of vehicles and penetration enhancers.In vitro anti-LPS dose determination of ketorolac tromethamine and in vivo safety of repeated dosing in healthy horses.Characterization of forced degradation products of ketorolac tromethamine using LC/ESI/Q/TOF/MS/MS and in silico toxicity prediction.
P2860
Q34148370-88C9554D-6D04-4565-BFAD-EC4076C0BC6DQ35753000-4CBCC249-380B-46DC-A53E-EA6A4D0093F3Q36188248-99A6FD18-9020-43B8-86FD-A4E624BB822FQ36542927-4AA070BF-2AF5-4A19-BAF2-8DF2EF811B37Q37360791-97C587C3-E63A-4F80-A991-3742FC7CF0D0Q37646469-63CE0437-3C30-4635-8661-A43C657DEEC5Q37650784-B27E9C3A-B926-4DDA-A593-FD185390D539Q37995532-72F63743-34A0-4D10-A096-75F3EEC0C853Q38290414-B9D9BBBF-B7B2-4CD0-9D0F-88686E69F9FEQ38672359-E9EE5E03-A9C0-4609-A0A3-5635B5F2DEA5Q39257669-7C35C2D0-A9D7-4C39-8ADB-83883852B6F8Q39518672-B941B357-FAEA-4F36-A6C0-DEB19466BA65Q41962683-8D95C646-EF69-4D7E-87D8-AB87B8B5AA17Q41967727-7547E646-186B-41E2-AC15-E9FD4BFEB0B2Q41989429-BD56544F-9FF3-48D4-A28C-F3D82C33FE8EQ42731706-17CD2CC4-C13B-496D-9302-53B14685B18DQ45000999-4982E9EC-B05A-4975-9260-B0F54EF9EAEBQ48296480-FEDAAEFD-6FDE-46AE-9C05-5FEA8B07AED8Q53090277-CBE63936-A37B-4159-A9B1-B3F40831DC44
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Minimising the adverse effects of ketorolac.
@ast
Minimising the adverse effects of ketorolac.
@en
type
label
Minimising the adverse effects of ketorolac.
@ast
Minimising the adverse effects of ketorolac.
@en
prefLabel
Minimising the adverse effects of ketorolac.
@ast
Minimising the adverse effects of ketorolac.
@en
P1433
P1476
Minimising the adverse effects of ketorolac.
@en
P2093
D I Reinhart
P304
P356
10.2165/00002018-200022060-00007
P577
2000-06-01T00:00:00Z
P6179
1012537268